Products
Online Inquiry
UM-164
Cat. No.:
0225LY-0535
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
UM-164 is a potent c-Src inhibitor (Kd = 2.7 nM) that also provides effective inhibition of p38α and p38β.
Synonym:
UM164; DAS-DFGO-II; 903564-48-7; 2-[[6-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-5-thiazolecarboxamide; 2-((6-(4-(2-Hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)thiazole-5-carboxamide; 2-[[6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-1,3-thiazole-5-carboxamide
CAS No.:
903564-48-7
Compound CID:
11714353
Formula:
C30H31F3N8O3S
Formula Weight:
640.68
Specification
Targets&IC50:
c-Src: 2.7 nM
Relative Density:
1.433 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
UM-164 can be used in breast cancer research to evaluate its dual inhibition of c-Src and p38 MAPK pathways.
Library Information
Target:
Src; p38 MAPK
Receptor:
c-Src; p38α; p38β; Src
Pathways:
MAPK; Autophagy; Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-7
Plate Location:
h9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
6.41 mg/mL; 10 mM
ALogP:
4.501
HBA_Count:
5
HBD_Count:
4
Rotatable Bond:
10
